EUVIMEDEUVIMED entdecken
Open Access

Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer

Clemens Hinterleitner iD, Valentin J A Barthet iD, Hailey V Goldberg iD, Kristen C Vogt iD, Ana Marie Perea iD, Logan R Hillger iD, Stephen Ruiz iD, Domhnall McHugh iD, Yu-Jui Ho iD, Almudena Chaves-Perez, Maria Skamagki iD, Sara Flowers und 16 weitere

Science · 2026

DOI: 10.1126/science.aeg4791 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science, 2026. Verfasst von Clemens Hinterleitner und 27 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Cellular Senescence, P-Selectin, Liver Cirrhosis, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCI NIH HHS, Howard Hughes Medical Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibrotic remodeling of tissues and tumors establishes immunosuppressive microenvironments that drive organ dysfunction and, in cancer, limit response to immunotherapy. Senescent-like cells are conserved drivers of fibrosis and therapeutic targets, yet their functional heterogeneity complicates therapeutic intervention. Here, we show that P-selectin is expressed by a subset of senescent-like cells in fibrotic tissues and tumors. Leveraging fucoidan-based nanoparticles that bind P-selectin, we developed senescence-modulating nanoparticles (SMNPs) to selectively target these disease-associated states. SMNPs exerted potent antifibrotic and immunomodulatory effects while improving the therapeutic index. Mechanistically, we identified a pathogenic, immunosuppressive macrophage population as a functional target in vivo. In fibrotic tumors, niche remodeling restored immune infiltration and sensitized tumors to immune checkpoint–based therapies. These findings establish SMNPs as a generalizable strategy to target pathogenic senescent cell subsets across fibrosis and cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cellular SenescenceP-SelectinLiver CirrhosisCarcinoma, HepatocellularLiver NeoplasmsPulmonary FibrosisLung NeoplasmsNanoparticle Drug Delivery SystemCarcinoma, Non-Small-Cell LungAnimalsHumansMiceCell Line, TumorImmunotherapyMacrophagesPolysaccharidesTumor MicroenvironmentMaleMice, Inbred C57BLAniline CompoundsSulfonamidesAcetamidesIndolesPiperidines

Substanzen

fucoidanP-SelectinPolysaccharidesNanoparticle Drug Delivery SystemnavitoclaxdBET6Aniline CompoundsSulfonamidesAcetamidesIndoles

Autor:innen und Institutionen

  • Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY, USA.
  • Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Tri-Institutional PhD Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Cancer Engineering Program, Gerstner Sloan Kettering School for Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

ORCID-Profile: Clemens Hinterleitner, Valentin J A Barthet, Hailey V Goldberg, Kristen C Vogt, Ana Marie Perea, Logan R Hillger, Stephen Ruiz, Domhnall McHugh, Yu-Jui Ho, Maria Skamagki, Hannah C Styers, Natasha Rekhtman, Xueqian Zhuang, Gabriel Dessotti Barretto, Xiang Li, Jadae T Watson, Tuomas Tammela, Rui Gardner, Charles M Rudin, Paul B Romesser, Matthew J Bott, Aveline Filliol, Daniel A Heller, Scott W Lowe

Förderung

  • NIGMS NIH HHS
  • NCI NIH HHS
  • Howard Hughes Medical Institute
  • NINDS NIH HHS
  • NIA NIH HHS
  • National Science Foundation
  • National Institutes of Health
  • American Cancer Society

Zitieren

APA

Hinterleitner, C., Barthet, V. J. A., Goldberg, H. V., Vogt, K. C., Perea, A. M., Hillger, L. R., Ruiz, S., McHugh, D., Ho, Y. J., Chaves-Perez, A., Skamagki, M., Flowers, S., Styers, H. C., Rekhtman, N., Zhuang, X., Dessotti Barretto, G., Li, X., Watson, J. T., Luan, W., …, & Lowe, S. W. (2026). Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer. Science. https://doi.org/10.1126/science.aeg4791

Vancouver

Hinterleitner C, Barthet VJA, Goldberg HV, Vogt KC, Perea AM, Hillger LR, et al. Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer. Science. 2026. doi:10.1126/science.aeg4791

BibTeX
@article{Hinterleitner2026,
  author = {Hinterleitner, Clemens and Barthet, Valentin J A and Goldberg, Hailey V and Vogt, Kristen C and Perea, Ana Marie and Hillger, Logan R and Ruiz, Stephen and McHugh, Domhnall and Ho, Yu-Jui and Chaves-Perez, Almudena and Skamagki, Maria and Flowers, Sara and Styers, Hannah C and Rekhtman, Natasha and Zhuang, Xueqian and Dessotti Barretto, Gabriel and Li, Xiang and Watson, Jadae T and Luan, Wei and Simon, Janelle and Tammela, Tuomas and Gardner, Rui and Rudin, Charles M and Romesser, Paul B and Bott, Matthew J and Filliol, Aveline and Heller, Daniel A and Lowe, Scott W},
  title = {Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer},
  journal = {Science},
  year = {2026},
  doi = {10.1126/science.aeg4791}
}
Kostenlos starten →